This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
HDAC inhibitor developer Acetylon raises $12.4mm in Series B round; closes at $28mm
Acetylon Pharmaceuticals Inc. (targeting class II-selective histone deacetylases for the treatment of cancer, inflammation, neurodegeneration, genetic protein disorders, and infectious diseases) has raised $12.4mm towards a Series B financing that could total as much as $30mm according to the Form D filing. A group of 23 backers participated.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?